Logo

Lupin Plans to Launch Two of its Biosimilars in the US

Share this

Lupin Plans to Launch Two of its Biosimilars in the US

Shots:

  • Lupin is planning for EU approval of etanercept biosimilar in Mar 2020 with its expected launch in July 2020 in European markets- further planning its launch in the US and has also received approval in Japan in Mar 2019
  • Additionally- Lupin has also signed an agreement with Mylan to launch its drug in Asia- Australia- Europe- and New Zealand
  • Etanercept is a mAb targeting inflammatory cytokine tumor necrosis factor (TNF) and can be used to treat various forms of arthritis. Lupin also plans to file the approval of etanercept and pegfilgrastim biosimilars in the US in Q4 of the same year

Click here to­ read full press release/ article | Ref: Gabi | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions